NCT00170794已完成3 期
A One Year, Multicenter, Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 主要终点
- Comparing calculated glomerular filtration rate (GFR) at Month 3 (Week 12) to Baseline and by comparing the daily cyclosporine dose at Month 3 (Week 12) to Baseline.
研究概览
简要总结
The purpose of the study is to determine the extent of cyclosporine microemulsion dose reduction required to maintain stable renal function in maintenance cardiac transplant recipients, after initiation of everolimus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female cardiac transplant recipients, 18-70 years old, with established cardiac allograft vasculopathy or at risk to develop a cardiac allograft vasculopathy.
- •Patients who are more than 12 months post-transplant and who are receiving a cyclosporine microemulsion-based immunosuppressive regimen with/without azathioprine /mycophenolate mofetil, with/without steroids.
- •Patients need to have stable renal function with a calculated GFR exceeding 40 ml/min (Nankivell).
- •Patients without a biopsy-proven acute rejection ≥ grade 2, within 12 months prior to study entry.
- •Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment. Effective contraception must be used during the trial and for 4 weeks following discontinuation of the study medication, even where there has been a history of infertility.
- •Patients who are willing and able to participate in the full course of the study and from whom written informed consent has been obtained.
排除标准
- •Patients who are recipients of multiple solid organ transplants.
- •Patients with a calculated GFR of less than 40 ml/min.
- •Patients with a biopsy-proven acute rejection episode ≥ 2 within 12 months prior to study entry.
- •Patients who had received any investigational drug within 4 weeks prior to study entry.
- •Patients currently being treated with sirolimus or having a history of prior therapy or having a hypersensitivity to drug similar to everolimus.
- •Patient with a platelet count of < 50,000/mm3 or with a white blood cell count of ≤ 2,500/mm3 or with a hemoglobin value < 10 g/dL.
- •Presence of severe hypercholesterolemia (≥ 9.1 mmol/L) or hypertriglyceridemia (≥ 8.55 mmol/L).
- •Patient with NYHA class IV heart failure, or with left ventricular ejection fraction <30%. Patients with life-threatening cardiac allograft vasculopathy and/or graft dysfunction (life expectancy 1 year).
- •Patients with severe systemic infections.
- •Patients who are known to have HBsAg or HCV positive hepatitis, or who are HIV positive. Serology results obtained within 6 months prior to study entry are acceptable. If results cannot be obtained prior to study entry, a sample must be retained for later analysis. This stored sample will be destroyed at the end of study.
- •Patients with any past (within the last 5 years) or present malignancy other than non-melanotic skin cancer.
- •Existence of a co-morbid condition likely to result in death prior to study completion
- •Symptoms of significant mental illness, which in the opinion of the investigator may interfere with the patient's ability to comply with the protocol. History of drug or alcohol abuse within 1 year of baseline.
- •Inability to cooperate or communicate with the investigator.
- •Female patients of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, or who are unwilling to use effective means of contraception.
结局指标
主要结局
Comparing calculated glomerular filtration rate (GFR) at Month 3 (Week 12) to Baseline and by comparing the daily cyclosporine dose at Month 3 (Week 12) to Baseline.
次要结局
- Safety laboratory tests including lipid profiles, hematology and proteinuria.
- Incidence of acute rejection episode greater than or equal to grade 3A.
- Incidence of premature study treatment discontinuation.
- Incidence of serious adverse avents (SAEs).
- Incidence of admission to the hospital.
研究者
相似试验
已完成
4 期
Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant RecipientsLiver TransplantNCT00171509Novartis61
已完成
4 期
Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation RecipientsKidney TransplantNCT00171496Novartis693
终止
4 期
Randomized Study to Reduce Calcineurininhibitor Toxicity in Pediatric and Adolescent Kidney Transplant RecipientsKidney TransplantNCT00663455University of Erlangen-Nürnberg Medical School50
已完成
3 期
Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant PatientsKidney TransplantationPrimary PreventionKidney FailureNCT00213590University Hospital, Rouen208
已完成
不适用
Clinical trial of oral microemulsion ciclosporin in severe acute ulcerative colitisUlcerative colitisISRCTN12342884Medical Research Council (MRC) (UK)